Skip to main content
Top
Published in: Endocrine 3/2016

01-12-2016 | Original Article

Obesity treatment by very low-calorie-ketogenic diet at two years: reduction in visceral fat and on the burden of disease

Authors: Basilio Moreno, Ana B Crujeiras, Diego Bellido, Ignacio Sajoux, Felipe F Casanueva

Published in: Endocrine | Issue 3/2016

Login to get access

Abstract

The long-term effect of therapeutic diets in obesity treatment is a challenge at present. The current study aimed to evaluate the long-term effect of a very low-calorie-ketogenic (VLCK) diet on excess adiposity. Especial focus was set on visceral fat mass, and the impact on the individual burden of disease. A group of obese patients (n = 45) were randomly allocated in two groups: either the very low-calorie-ketogenic diet group (n = 22), or a standard low-calorie diet group; (n = 23). Both groups received external support. Adiposity parameters and the cumulative number of months of successful weight loss (5 or 10 %) over a 24-month period were quantified. The very low-calorie-ketogenic diet induced less than 2 months of mild ketosis and significant effects on body weight at 6, 12, and 24 months. At 24 months, a trend to regress to baseline levels was observed; however, the very low-calorie-ketogenic diet induced a greater reduction in body weight (−12.5 kg), waist circumference (−11.6 cm), and body fat mass (−8.8 kg) than the low-calorie diet (−4.4 kg, −4.1 cm, and −3.8 kg, respectively; p < 0.001). Interestingly, a selective reduction in visceral fat measured by a specific software of dual-energy x-ray absorptiometry (DEXA)-scan (−600 g vs. −202 g; p < 0.001) was observed. Moreover, the very low-calorie-ketogenic diet group experienced a reduction in the individual burden of obesity because reduction in disease duration. Very low-calorie-ketogenic diet patients were 500 months with 5 % weight lost vs. the low-calorie diet group (350 months; p < 0.001). In conclusion, a very low-calorie-ketogenic diet was effective 24 months later, with a decrease in visceral adipose tissue and a reduction in the individual burden of disease.
Literature
1.
go back to reference K.M. Flegal, M.D. Carroll, B.K. Kit, C.L. Ogden, Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. Jama. 307, 491–497 (2012)CrossRefPubMed K.M. Flegal, M.D. Carroll, B.K. Kit, C.L. Ogden, Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. Jama. 307, 491–497 (2012)CrossRefPubMed
2.
go back to reference J.L. Gutierrez-Fisac, P. Guallar-Castillon, L.M. Leon-Munoz, A. Graciani, J.R. Banegas, F. Rodriguez-Artalejo, Prevalence of general and abdominal obesity in the adult population of Spain, 2008-2010: the ENRICA study. Obes. Rev. 13, 388–392 (2010)CrossRef J.L. Gutierrez-Fisac, P. Guallar-Castillon, L.M. Leon-Munoz, A. Graciani, J.R. Banegas, F. Rodriguez-Artalejo, Prevalence of general and abdominal obesity in the adult population of Spain, 2008-2010: the ENRICA study. Obes. Rev. 13, 388–392 (2010)CrossRef
3.
go back to reference F.F. Casanueva, B. Moreno, R. Rodriguez-Azeredo, C. Massien, P. Conthe, X. Formiguera, V. Barrios, B. Balkau, Relationship of abdominal obesity with cardiovascular disease, diabetes and hyperlipidaemia in Spain. Clin. Endocrinol. 73, 35–40 (2010) F.F. Casanueva, B. Moreno, R. Rodriguez-Azeredo, C. Massien, P. Conthe, X. Formiguera, V. Barrios, B. Balkau, Relationship of abdominal obesity with cardiovascular disease, diabetes and hyperlipidaemia in Spain. Clin. Endocrinol. 73, 35–40 (2010)
5.
go back to reference G. Fruhbeck, V. Yumuk. Obesity: a gateway disease with a rising prevalence. Obes. Facts 7 Suppl 2, 33–36 (2014)PubMed G. Fruhbeck, V. Yumuk. Obesity: a gateway disease with a rising prevalence. Obes. Facts 7 Suppl 2, 33–36 (2014)PubMed
7.
go back to reference J.E. Blundell, J. Hebebrand, J.M. Oppert, What is the value of obesity research? Obes. Facts 3, 279–282 (2010)CrossRefPubMed J.E. Blundell, J. Hebebrand, J.M. Oppert, What is the value of obesity research? Obes. Facts 3, 279–282 (2010)CrossRefPubMed
8.
go back to reference G.A. Bray, G. Fruhbeck, D.H. Ryan, J.P. Wilding Management of obesity. Lancet. (2016). G.A. Bray, G. Fruhbeck, D.H. Ryan, J.P. Wilding Management of obesity. Lancet. (2016).
9.
go back to reference W.T. Cefalu, G.A. Bray, P.D. Home, W.T. Garvey, S. Klein, F.X. Pi-Sunyer, F.B. Hu, I. Raz, L. Van Gaal, B.M. Wolfe, D.H. Ryan, Advances in the science, treatment, and prevention of the disease of obesity: reflections from a diabetes care editors’ expert forum. Diabetes Care 38, 1567–1582 (2015)CrossRefPubMedPubMedCentral W.T. Cefalu, G.A. Bray, P.D. Home, W.T. Garvey, S. Klein, F.X. Pi-Sunyer, F.B. Hu, I. Raz, L. Van Gaal, B.M. Wolfe, D.H. Ryan, Advances in the science, treatment, and prevention of the disease of obesity: reflections from a diabetes care editors’ expert forum. Diabetes Care 38, 1567–1582 (2015)CrossRefPubMedPubMedCentral
10.
go back to reference G. Di Dalmazi, V. Vicennati, R. Pasquali, U. Pagotto, The unrelenting fall of the pharmacological treatment of obesity. Endocrine 44, 598–609 (2013)CrossRefPubMed G. Di Dalmazi, V. Vicennati, R. Pasquali, U. Pagotto, The unrelenting fall of the pharmacological treatment of obesity. Endocrine 44, 598–609 (2013)CrossRefPubMed
11.
go back to reference J.P. Despres, A. Golay, L. Sjostrom, Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N. Engl. J. Med. 353, 2121–2134 (2005)CrossRefPubMed J.P. Despres, A. Golay, L. Sjostrom, Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N. Engl. J. Med. 353, 2121–2134 (2005)CrossRefPubMed
12.
go back to reference R.V. Dvorak, A.M. Sharma, A. Astrup, Anti-obesity drugs: to be or not to be? Obes. Rev. 11, 833–834 (2010)CrossRefPubMed R.V. Dvorak, A.M. Sharma, A. Astrup, Anti-obesity drugs: to be or not to be? Obes. Rev. 11, 833–834 (2010)CrossRefPubMed
13.
go back to reference M. Hopkins, N.A. King, J.E. Blundell, Acute and long-term effects of exercise on appetite control: is there any benefit for weight control? Curr. Opin. Clin. Nutr. Metab. Care. 13, 635–640 (2010)CrossRefPubMed M. Hopkins, N.A. King, J.E. Blundell, Acute and long-term effects of exercise on appetite control: is there any benefit for weight control? Curr. Opin. Clin. Nutr. Metab. Care. 13, 635–640 (2010)CrossRefPubMed
14.
go back to reference L.F. Van Gaal, A.M. Rissanen, A.J. Scheen, O. Ziegler, S. Rossner, Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365, 1389–1397 (2005)CrossRefPubMed L.F. Van Gaal, A.M. Rissanen, A.J. Scheen, O. Ziegler, S. Rossner, Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365, 1389–1397 (2005)CrossRefPubMed
15.
go back to reference G.A. Bray, L.A. Tartaglia, Medicinal strategies in the treatment of obesity. Nature 404, 672–677 (2000)PubMed G.A. Bray, L.A. Tartaglia, Medicinal strategies in the treatment of obesity. Nature 404, 672–677 (2000)PubMed
16.
go back to reference A. Astrup, T. Meinert Larsen, A. Harper, Atkins and other low-carbohydrate diets: hoax or an effective tool for weight loss? Lancet 364, 897–899 (2004)CrossRefPubMed A. Astrup, T. Meinert Larsen, A. Harper, Atkins and other low-carbohydrate diets: hoax or an effective tool for weight loss? Lancet 364, 897–899 (2004)CrossRefPubMed
17.
go back to reference A.B. Crujeiras, M.A. Zulet, I. Abete, M. Amil, M.C. Carreira, J.A. Martinez, F.F. Casanueva, Interplay of atherogenic factors, protein intake and betatrophin levels in obese-metabolic syndrome patients treated with hypocaloric diets. Int. J. Obes. 40, 403–410 (2015)CrossRef A.B. Crujeiras, M.A. Zulet, I. Abete, M. Amil, M.C. Carreira, J.A. Martinez, F.F. Casanueva, Interplay of atherogenic factors, protein intake and betatrophin levels in obese-metabolic syndrome patients treated with hypocaloric diets. Int. J. Obes. 40, 403–410 (2015)CrossRef
18.
go back to reference D. Paddon-Jones, E. Westman, R.D. Mattes, R.R. Wolfe, A. Astrup, M. Westerterp-Plantenga, Protein, weight management, and satiety. Am. J. Clin. Nutr. 87, 1558S–1561S (2008)PubMed D. Paddon-Jones, E. Westman, R.D. Mattes, R.R. Wolfe, A. Astrup, M. Westerterp-Plantenga, Protein, weight management, and satiety. Am. J. Clin. Nutr. 87, 1558S–1561S (2008)PubMed
20.
go back to reference A. Al-Khalifa, T.C. Mathew, N.S. Al-Zaid, E. Mathew, H.M. Dashti, Therapeutic role of low-carbohydrate ketogenic diet in diabetes. Nutrition 25, 1177–1185 (2009)CrossRefPubMed A. Al-Khalifa, T.C. Mathew, N.S. Al-Zaid, E. Mathew, H.M. Dashti, Therapeutic role of low-carbohydrate ketogenic diet in diabetes. Nutrition 25, 1177–1185 (2009)CrossRefPubMed
21.
go back to reference H.M. Dashti, T.C. Mathew, M. Khadada, M. Al-Mousawi, H. Talib, S.K. Asfar, A.I. Behbahani, N.S. Al-Zaid, Beneficial effects of ketogenic diet in obese diabetic subjects. Mol. Cell. Biochem. 302, 249–256 (2007)CrossRefPubMed H.M. Dashti, T.C. Mathew, M. Khadada, M. Al-Mousawi, H. Talib, S.K. Asfar, A.I. Behbahani, N.S. Al-Zaid, Beneficial effects of ketogenic diet in obese diabetic subjects. Mol. Cell. Biochem. 302, 249–256 (2007)CrossRefPubMed
22.
go back to reference M.J. Sharman, W.J. Kraemer, D.M. Love, N.G. Avery, A.L. Gomez, T.P. Scheett, J.S. Volek, A ketogenic diet favorably affects serum biomarkers for cardiovascular disease in normal-weight men. J. Nutr. 132, 1879–1885 (2002)PubMed M.J. Sharman, W.J. Kraemer, D.M. Love, N.G. Avery, A.L. Gomez, T.P. Scheett, J.S. Volek, A ketogenic diet favorably affects serum biomarkers for cardiovascular disease in normal-weight men. J. Nutr. 132, 1879–1885 (2002)PubMed
23.
go back to reference B.G. Allen, S.K. Bhatia, C.M. Anderson, J.M. Eichenberger-Gilmore, Z.A. Sibenaller, K.A. Mapuskar, J.D. Schoenfeld, J.M. Buatti, D.R. Spitz, M.A. Fath, Ketogenic diets as an adjuvant cancer therapy: history and potential mechanism. Redox. Biol. 2C, 963–970 (2014) B.G. Allen, S.K. Bhatia, C.M. Anderson, J.M. Eichenberger-Gilmore, Z.A. Sibenaller, K.A. Mapuskar, J.D. Schoenfeld, J.M. Buatti, D.R. Spitz, M.A. Fath, Ketogenic diets as an adjuvant cancer therapy: history and potential mechanism. Redox. Biol. 2C, 963–970 (2014)
24.
go back to reference A.F. Branco, A. Ferreira, R.F. Simoes, S. Magalhaes-Novais, C. Zehowski, E. Cope, A.M. Silva, D. Pereira, V.A. Sardao, T. Cunha-Oliveira, Ketogenic diets: from cancer to mitochondrial diseases and beyond. Eur. J. Clin. Invest. 46, 285–298 (2016)CrossRefPubMed A.F. Branco, A. Ferreira, R.F. Simoes, S. Magalhaes-Novais, C. Zehowski, E. Cope, A.M. Silva, D. Pereira, V.A. Sardao, T. Cunha-Oliveira, Ketogenic diets: from cancer to mitochondrial diseases and beyond. Eur. J. Clin. Invest. 46, 285–298 (2016)CrossRefPubMed
25.
go back to reference N.B. Bueno, I.S. de Melo, S.L. de Oliveira, T. da Rocha Ataide, Very-low-carbohydrate ketogenic diet v. low-fat diet for long-term weight loss: a meta-analysis of randomised controlled trials. Br. J. Nutr. 110, 1178–1187 (2013)CrossRefPubMed N.B. Bueno, I.S. de Melo, S.L. de Oliveira, T. da Rocha Ataide, Very-low-carbohydrate ketogenic diet v. low-fat diet for long-term weight loss: a meta-analysis of randomised controlled trials. Br. J. Nutr. 110, 1178–1187 (2013)CrossRefPubMed
26.
go back to reference B. Moreno, D. Bellido, I. Sajoux, A. Goday, D. Saavedra, A.B. Crujeiras, F.F. Casanueva, Comparison of a very low-calorie-ketogenic diet with a standard low-calorie diet in the treatment of obesity. Endocrine 47, 793–805 (2014)CrossRefPubMed B. Moreno, D. Bellido, I. Sajoux, A. Goday, D. Saavedra, A.B. Crujeiras, F.F. Casanueva, Comparison of a very low-calorie-ketogenic diet with a standard low-calorie diet in the treatment of obesity. Endocrine 47, 793–805 (2014)CrossRefPubMed
27.
go back to reference A. Astrup, S. Rossner, Lessons from obesity management programmes: greater initial weight loss improves long-term maintenance. Obes. Rev. 1, 17–19 (2000)CrossRefPubMed A. Astrup, S. Rossner, Lessons from obesity management programmes: greater initial weight loss improves long-term maintenance. Obes. Rev. 1, 17–19 (2000)CrossRefPubMed
28.
go back to reference S.G. Camps, S.P. Verhoef, K.R. Westerterp, Weight loss, weight maintenance, and adaptive thermogenesis. Am. J. Clin. Nutr. 97, 990–994 (2013)CrossRefPubMed S.G. Camps, S.P. Verhoef, K.R. Westerterp, Weight loss, weight maintenance, and adaptive thermogenesis. Am. J. Clin. Nutr. 97, 990–994 (2013)CrossRefPubMed
29.
go back to reference A.B. Crujeiras, E. Goyenechea, I. Abete, M. Lage, M.C. Carreira, J.A. Martinez, F.F. Casanueva, Weight regain after a diet-induced loss is predicted by higher baseline leptin and lower ghrelin plasma levels. J. Clin. Endocrinol. Metab. 95, 5037–5044 (2010)CrossRefPubMed A.B. Crujeiras, E. Goyenechea, I. Abete, M. Lage, M.C. Carreira, J.A. Martinez, F.F. Casanueva, Weight regain after a diet-induced loss is predicted by higher baseline leptin and lower ghrelin plasma levels. J. Clin. Endocrinol. Metab. 95, 5037–5044 (2010)CrossRefPubMed
30.
go back to reference A.B. Crujeiras, M. Pardo, R.R. Arturo, S. Navas-Carretero, M.A. Zulet, J.A. Martinez, F.F. Casanueva, Longitudinal variation of circulating irisin after an energy restriction-induced weight loss and following weight regain in obese men and women. Am. J. Hum. Biol. 26, 198–207 (2014)CrossRefPubMed A.B. Crujeiras, M. Pardo, R.R. Arturo, S. Navas-Carretero, M.A. Zulet, J.A. Martinez, F.F. Casanueva, Longitudinal variation of circulating irisin after an energy restriction-induced weight loss and following weight regain in obese men and women. Am. J. Hum. Biol. 26, 198–207 (2014)CrossRefPubMed
31.
go back to reference A.B. Crujeiras, M.A. Zulet, P. Lopez-Legarrea, R. de la Iglesia, M. Pardo, M.C. Carreira, J.A. Martinez, F.F. Casanueva, Association between circulating irisin levels and the promotion of insulin resistance during the weight maintenance period after a dietary weight-lowering program in obese patients. Metabolism 63, 520–531 (2014)CrossRefPubMed A.B. Crujeiras, M.A. Zulet, P. Lopez-Legarrea, R. de la Iglesia, M. Pardo, M.C. Carreira, J.A. Martinez, F.F. Casanueva, Association between circulating irisin levels and the promotion of insulin resistance during the weight maintenance period after a dietary weight-lowering program in obese patients. Metabolism 63, 520–531 (2014)CrossRefPubMed
32.
go back to reference P.S. Maclean, A. Bergouignan, M.A. Cornier, M.R. Jackman, Biology’s response to dieting: the impetus for weight regain. Am. J. Physiol. Regul. Integr. Comp. Physiol. 301, R581–600 (2011)CrossRefPubMedPubMedCentral P.S. Maclean, A. Bergouignan, M.A. Cornier, M.R. Jackman, Biology’s response to dieting: the impetus for weight regain. Am. J. Physiol. Regul. Integr. Comp. Physiol. 301, R581–600 (2011)CrossRefPubMedPubMedCentral
33.
go back to reference R.R. Wing, S. Phelan, Long-term weight loss maintenance. Am. J. Clin. Nutr. 82, 222S–225S (2005)PubMed R.R. Wing, S. Phelan, Long-term weight loss maintenance. Am. J. Clin. Nutr. 82, 222S–225S (2005)PubMed
34.
go back to reference R.R. Wing, D.F. Tate, A.A. Gorin, H.A. Raynor, J.L. Fava, A self-regulation program for maintenance of weight loss. N. Engl. J. Med. 355, 1563–1571 (2006)CrossRefPubMed R.R. Wing, D.F. Tate, A.A. Gorin, H.A. Raynor, J.L. Fava, A self-regulation program for maintenance of weight loss. N. Engl. J. Med. 355, 1563–1571 (2006)CrossRefPubMed
35.
go back to reference FAO/WHO/UNU. Energy and Protein requirements. Technical Report Series N° 724. World Health Organization, Geneva (1985) FAO/WHO/UNU. Energy and Protein requirements. Technical Report Series N° 724. World Health Organization, Geneva (1985)
36.
go back to reference M. Gargallo Fernandez, J.B. Marset, I.B. Lesmes, J.Q. Izquierdo, X.F. Sala, J. Salas-Salvado, [FESNAD-SEEDO consensus summary: evidence-based nutritional recommendations for the prevention and treatment of overweight and obesity in adults]. Endocrinol. Nutr. 59, 429–437 (2011)CrossRef M. Gargallo Fernandez, J.B. Marset, I.B. Lesmes, J.Q. Izquierdo, X.F. Sala, J. Salas-Salvado, [FESNAD-SEEDO consensus summary: evidence-based nutritional recommendations for the prevention and treatment of overweight and obesity in adults]. Endocrinol. Nutr. 59, 429–437 (2011)CrossRef
38.
go back to reference SCOOP-VLCD task 7.3 Reports on tasks for scientific cooperation. Collection of data on products intended for use in very-low-calorie-diets. Report Brussels European Comission, September (2002) SCOOP-VLCD task 7.3 Reports on tasks for scientific cooperation. Collection of data on products intended for use in very-low-calorie-diets. Report Brussels European Comission, September (2002)
39.
go back to reference S. Kaul, M.P. Rothney, D.M. Peters, W.K. Wacker, C.E. Davis, M.D. Shapiro, D.L. Ergun, Dual-energy X-ray absorptiometry for quantification of visceral fat. Obesity 20, 1313–1318 (2012)CrossRefPubMedPubMedCentral S. Kaul, M.P. Rothney, D.M. Peters, W.K. Wacker, C.E. Davis, M.D. Shapiro, D.L. Ergun, Dual-energy X-ray absorptiometry for quantification of visceral fat. Obesity 20, 1313–1318 (2012)CrossRefPubMedPubMedCentral
40.
go back to reference L.K. Micklesfield, J.H. Goedecke, M. Punyanitya, K.E. Wilson, T.L. Kelly, Dual-energy X-ray performs as well as clinical computed tomography for the measurement of visceral fat. Obesity 20, 1109–1114 (2012)CrossRefPubMedPubMedCentral L.K. Micklesfield, J.H. Goedecke, M. Punyanitya, K.E. Wilson, T.L. Kelly, Dual-energy X-ray performs as well as clinical computed tomography for the measurement of visceral fat. Obesity 20, 1109–1114 (2012)CrossRefPubMedPubMedCentral
41.
go back to reference Kelly TL, Wilson KE, Ruth CR Estimating visceral fat by dual-energy X-ray absorptiometry. US patent application number US2010-0234719 Hologic, Inc. (2010). Kelly TL, Wilson KE, Ruth CR Estimating visceral fat by dual-energy X-ray absorptiometry. US patent application number US2010-0234719 Hologic, Inc. (2010).
42.
go back to reference Kelly TL, Wilson KE, Ruth CR Visceral fat measurement. US patent application number US2011-0235881 Hologic, Inc. (2011). Kelly TL, Wilson KE, Ruth CR Visceral fat measurement. US patent application number US2011-0235881 Hologic, Inc. (2011).
43.
go back to reference I. Shai, D. Schwarzfuchs, Y. Henkin, D.R. Shahar, S. Witkow, I. Greenberg, R. Golan, D. Fraser, A. Bolotin, H. Vardi, O. Tangi-Rozental, R. Zuk-Ramot, B. Sarusi, D. Brickner, Z. Schwartz, E. Sheiner, R. Marko, E. Katorza, J. Thiery, G.M. Fiedler, M. Bluher, M. Stumvoll, M.J. Stampfer, Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet. N. Engl. J. Med. 359, 229–241 (2008)CrossRefPubMed I. Shai, D. Schwarzfuchs, Y. Henkin, D.R. Shahar, S. Witkow, I. Greenberg, R. Golan, D. Fraser, A. Bolotin, H. Vardi, O. Tangi-Rozental, R. Zuk-Ramot, B. Sarusi, D. Brickner, Z. Schwartz, E. Sheiner, R. Marko, E. Katorza, J. Thiery, G.M. Fiedler, M. Bluher, M. Stumvoll, M.J. Stampfer, Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet. N. Engl. J. Med. 359, 229–241 (2008)CrossRefPubMed
44.
go back to reference B. Cabia, S. Andrade, M.C. Carreira, F.F. Casanueva, A.B. Crujeiras, A role for novel adipose tissue-secreted factors in obesity-related carcinogenesis. Obes. Rev. 17, 361–376 (2016)CrossRefPubMed B. Cabia, S. Andrade, M.C. Carreira, F.F. Casanueva, A.B. Crujeiras, A role for novel adipose tissue-secreted factors in obesity-related carcinogenesis. Obes. Rev. 17, 361–376 (2016)CrossRefPubMed
45.
go back to reference M.C. Amato, G. Pizzolanti, V. Torregrossa, G. Misiano, S. Milano, C. Giordano, Visceral adiposity index (VAI) is predictive of an altered adipokine profile in patients with type 2 diabetes. PLoS One 9, e91969 (2014)CrossRefPubMedPubMedCentral M.C. Amato, G. Pizzolanti, V. Torregrossa, G. Misiano, S. Milano, C. Giordano, Visceral adiposity index (VAI) is predictive of an altered adipokine profile in patients with type 2 diabetes. PLoS One 9, e91969 (2014)CrossRefPubMedPubMedCentral
46.
go back to reference A.B. Crujeiras, B. Cabia, M.C. Carreira, M. Amil, J. Cueva, S. Andrade, L.M. Seoane, M. Pardo, A. Sueiro, J. Baltar, T. Morais, M.P. Monteiro, R. Lopez-Lopez, F.F. Casanueva, Secreted factors derived from obese visceral adipose tissue regulate the expression of breast malignant transformation genes. Int. J. Obes. 40, 514–523 (2015)CrossRef A.B. Crujeiras, B. Cabia, M.C. Carreira, M. Amil, J. Cueva, S. Andrade, L.M. Seoane, M. Pardo, A. Sueiro, J. Baltar, T. Morais, M.P. Monteiro, R. Lopez-Lopez, F.F. Casanueva, Secreted factors derived from obese visceral adipose tissue regulate the expression of breast malignant transformation genes. Int. J. Obes. 40, 514–523 (2015)CrossRef
47.
go back to reference I.J. Neeland, C.R. Ayers, A.K. Rohatgi, A.T. Turer, J.D. Berry, S.R. Das, G.L. Vega, A. Khera, D.K. McGuire, S.M. Grundy, J.A. de Lemos, Associations of visceral and abdominal subcutaneous adipose tissue with markers of cardiac and metabolic risk in obese adults. Obesity 21, E439–447 (2013)PubMedPubMedCentral I.J. Neeland, C.R. Ayers, A.K. Rohatgi, A.T. Turer, J.D. Berry, S.R. Das, G.L. Vega, A. Khera, D.K. McGuire, S.M. Grundy, J.A. de Lemos, Associations of visceral and abdominal subcutaneous adipose tissue with markers of cardiac and metabolic risk in obese adults. Obesity 21, E439–447 (2013)PubMedPubMedCentral
48.
go back to reference D. Vissers, W. Hens, J. Taeymans, J.P. Baeyens, J. Poortmans, L. Van Gaal, The effect of exercise on visceral adipose tissue in overweight adults: a systematic review and meta-analysis. PLoS One 8, e56415 (2013)CrossRefPubMedPubMedCentral D. Vissers, W. Hens, J. Taeymans, J.P. Baeyens, J. Poortmans, L. Van Gaal, The effect of exercise on visceral adipose tissue in overweight adults: a systematic review and meta-analysis. PLoS One 8, e56415 (2013)CrossRefPubMedPubMedCentral
49.
go back to reference I. Wolz, I. Hilker, R. Granero, S. Jimenez-Murcia, A.N. Gearhardt, C. Dieguez, F.F. Casanueva, A.B. Crujeiras, J.M. Menchon, F. Fernandez-Aranda, “Food Addiction” in Patients with Eating Disorders is Associated with Negative Urgency and Difficulties to Focus on Long-Term Goals. Front Psychol. 7, 61 (2016)CrossRefPubMedPubMedCentral I. Wolz, I. Hilker, R. Granero, S. Jimenez-Murcia, A.N. Gearhardt, C. Dieguez, F.F. Casanueva, A.B. Crujeiras, J.M. Menchon, F. Fernandez-Aranda, “Food Addiction” in Patients with Eating Disorders is Associated with Negative Urgency and Difficulties to Focus on Long-Term Goals. Front Psychol. 7, 61 (2016)CrossRefPubMedPubMedCentral
50.
go back to reference M.M. Ibrahim, Subcutaneous and visceral adipose tissue: structural and functional differences. Obes. Rev. 11, 11–18 (2010)CrossRefPubMed M.M. Ibrahim, Subcutaneous and visceral adipose tissue: structural and functional differences. Obes. Rev. 11, 11–18 (2010)CrossRefPubMed
51.
go back to reference B.L. Wajchenberg, D. Giannella-Neto, M.E. da Silva, R.F. Santos, Depot-specific hormonal characteristics of subcutaneous and visceral adipose tissue and their relation to the metabolic syndrome. Horm. Metab. Res. 34, 616–621 (2002)CrossRefPubMed B.L. Wajchenberg, D. Giannella-Neto, M.E. da Silva, R.F. Santos, Depot-specific hormonal characteristics of subcutaneous and visceral adipose tissue and their relation to the metabolic syndrome. Horm. Metab. Res. 34, 616–621 (2002)CrossRefPubMed
52.
go back to reference B. Bjorndal, L. Burri, V. Staalesen, J. Skorve, R.K. Berge, Different adipose depots: their role in the development of metabolic syndrome and mitochondrial response to hypolipidemic agents. J. Obes. 2011, 490650 (2011)CrossRefPubMedPubMedCentral B. Bjorndal, L. Burri, V. Staalesen, J. Skorve, R.K. Berge, Different adipose depots: their role in the development of metabolic syndrome and mitochondrial response to hypolipidemic agents. J. Obes. 2011, 490650 (2011)CrossRefPubMedPubMedCentral
53.
go back to reference L. Webber, D. Divajeva, T. Marsh, K. McPherson, M. Brown, G. Galea, J. Breda, The future burden of obesity-related diseases in the 53 WHO European-Region countries and the impact of effective interventions: a modelling study. BMJ Open 4, e004787 (2014)CrossRefPubMedPubMedCentral L. Webber, D. Divajeva, T. Marsh, K. McPherson, M. Brown, G. Galea, J. Breda, The future burden of obesity-related diseases in the 53 WHO European-Region countries and the impact of effective interventions: a modelling study. BMJ Open 4, e004787 (2014)CrossRefPubMedPubMedCentral
54.
go back to reference H.P. Booth, T.A. Prevost, A.J. Wright, M.C. Gulliford, Effectiveness of behavioural weight loss interventions delivered in a primary care setting: a systematic review and meta-analysis. Fam. Pract. 31, 643–653 (2014)CrossRefPubMedPubMedCentral H.P. Booth, T.A. Prevost, A.J. Wright, M.C. Gulliford, Effectiveness of behavioural weight loss interventions delivered in a primary care setting: a systematic review and meta-analysis. Fam. Pract. 31, 643–653 (2014)CrossRefPubMedPubMedCentral
55.
go back to reference A. Abdullah, R. Wolfe, J.U. Stoelwinder, M. de Courten, C. Stevenson, H.L. Walls, A. Peeters, The number of years lived with obesity and the risk of all-cause and cause-specific mortality. Int. J. Epidemiol. 40, 985–996 (2011)CrossRefPubMed A. Abdullah, R. Wolfe, J.U. Stoelwinder, M. de Courten, C. Stevenson, H.L. Walls, A. Peeters, The number of years lived with obesity and the risk of all-cause and cause-specific mortality. Int. J. Epidemiol. 40, 985–996 (2011)CrossRefPubMed
56.
go back to reference R.Z. Stolzenberg-Solomon, C. Schairer, S. Moore, A. Hollenbeck, D.T. Silverman, Lifetime adiposity and risk of pancreatic cancer in the NIH-AARP Diet and Health Study cohort. Am. J. Clin. Nutr. 98, 1057–1065 (2013)CrossRefPubMedPubMedCentral R.Z. Stolzenberg-Solomon, C. Schairer, S. Moore, A. Hollenbeck, D.T. Silverman, Lifetime adiposity and risk of pancreatic cancer in the NIH-AARP Diet and Health Study cohort. Am. J. Clin. Nutr. 98, 1057–1065 (2013)CrossRefPubMedPubMedCentral
57.
go back to reference J.P. Reis, C.M. Loria, C.E. Lewis, T.M. Powell-Wiley, G.S. Wei, J.J. Carr, J.G. Terry, K. Liu, Association between duration of overall and abdominal obesity beginning in young adulthood and coronary artery calcification in middle age. Jama. 310, 280–288 (2013)CrossRefPubMedPubMedCentral J.P. Reis, C.M. Loria, C.E. Lewis, T.M. Powell-Wiley, G.S. Wei, J.J. Carr, J.G. Terry, K. Liu, Association between duration of overall and abdominal obesity beginning in young adulthood and coronary artery calcification in middle age. Jama. 310, 280–288 (2013)CrossRefPubMedPubMedCentral
58.
go back to reference M. Arnold, N. Pandeya, G. Byrnes, A.G. Renehan, G.A. Stevens, M. Ezzati, J. Ferlay, J.J. Miranda, I. Romieu, R. Dikshit, D. Forman, I. Soerjomataram, Global burden of cancer attributable to high body-mass index in 2012: a population-based study. Lancet Oncol. 16, 36–46 (2015)CrossRefPubMed M. Arnold, N. Pandeya, G. Byrnes, A.G. Renehan, G.A. Stevens, M. Ezzati, J. Ferlay, J.J. Miranda, I. Romieu, R. Dikshit, D. Forman, I. Soerjomataram, Global burden of cancer attributable to high body-mass index in 2012: a population-based study. Lancet Oncol. 16, 36–46 (2015)CrossRefPubMed
59.
go back to reference J.A. Nazare, J. Smith, A.L. Borel, P. Aschner, P. Barter, L. Van Gaal, C.E. Tan, H.U. Wittchen, Y. Matsuzawa, T. Kadowaki, R. Ross, C. Brulle-Wohlhueter, N. Almeras, S.M. Haffner, B. Balkau, J.P. Despres, Usefulness of measuring both body mass index and waist circumference for the estimation of visceral adiposity and related cardiometabolic risk profile (from the INSPIRE ME IAA study). Am. J. Cardiol. 115, 307–315 (2015)CrossRefPubMed J.A. Nazare, J. Smith, A.L. Borel, P. Aschner, P. Barter, L. Van Gaal, C.E. Tan, H.U. Wittchen, Y. Matsuzawa, T. Kadowaki, R. Ross, C. Brulle-Wohlhueter, N. Almeras, S.M. Haffner, B. Balkau, J.P. Despres, Usefulness of measuring both body mass index and waist circumference for the estimation of visceral adiposity and related cardiometabolic risk profile (from the INSPIRE ME IAA study). Am. J. Cardiol. 115, 307–315 (2015)CrossRefPubMed
Metadata
Title
Obesity treatment by very low-calorie-ketogenic diet at two years: reduction in visceral fat and on the burden of disease
Authors
Basilio Moreno
Ana B Crujeiras
Diego Bellido
Ignacio Sajoux
Felipe F Casanueva
Publication date
01-12-2016
Publisher
Springer US
Published in
Endocrine / Issue 3/2016
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-016-1050-2

Other articles of this Issue 3/2016

Endocrine 3/2016 Go to the issue